Emerging Markets Earnings: Strong Showing For Bayer Despite China Nexavar Hiccup
This article was originally published in PharmAsia News
Executive Summary
Bayer slowly but surely nears the halfway mark for the proportion of overall sales from emerging markets with double-digit growth in the third quarter, though the company faced some hiccups related to Nexavar stocks in China
You may also be interested in...
U.K. Cancer Drug Fund May Shift To ‘Coverage With Evidence Development’-Style Approach
Fund would revaluate benefits – and pricing – of drugs it covers, adding extra layer of complexity to accessing new medicines for Britain’s cancer patients.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.
Southeast Asia 2014: Distribution, Manufacturing To The Fore
Southeast Asia in 2014 saw a continued push by several nations in the region to ink a Trans-Pacific Partnership pact that would potentially have a major impact on biological drugs. Also manufacturing and distribution saw a leap in the hub of Singapore as governments in the region ramped-up health spending.